vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Freedom Holding Corp. (FRHC). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $628.6M, roughly 1.5× Freedom Holding Corp.). Freedom Holding Corp. runs the higher net margin — 12.1% vs 0.7%, a 11.4% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -4.1%). Freedom Holding Corp. produced more free cash flow last quarter ($651.7M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 16.3%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Freedom Holding Corp. is an investment conglomerate registered in Nevada, USA. The company provides a range of services in retail financial securities brokerage and trading, asset management, capital markets, investment research and counseling, investment banking and underwriting services, mortgages, insurance, banking and other consumer services. Its main area of focus is in the American stock market, as well as the markets of Europe and Central Asia, mainly Kazakhstan.

ASTH vs FRHC — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.5× larger
ASTH
$950.5M
$628.6M
FRHC
Growing faster (revenue YoY)
ASTH
ASTH
+46.9% gap
ASTH
42.9%
-4.1%
FRHC
Higher net margin
FRHC
FRHC
11.4% more per $
FRHC
12.1%
0.7%
ASTH
More free cash flow
FRHC
FRHC
$657.7M more FCF
FRHC
$651.7M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
16.3%
FRHC

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ASTH
ASTH
FRHC
FRHC
Revenue
$950.5M
$628.6M
Net Profit
$6.6M
$76.2M
Gross Margin
96.0%
Operating Margin
1.9%
14.9%
Net Margin
0.7%
12.1%
Revenue YoY
42.9%
-4.1%
Net Profit YoY
184.4%
-2.6%
EPS (diluted)
$0.12
$1.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
FRHC
FRHC
Q4 25
$950.5M
$628.6M
Q3 25
$956.0M
$526.1M
Q2 25
$654.8M
$533.4M
Q1 25
$620.4M
$363.7M
Q4 24
$665.2M
$655.2M
Q3 24
$478.7M
$580.9M
Q2 24
$486.3M
$450.7M
Q1 24
$404.4M
$464.7M
Net Profit
ASTH
ASTH
FRHC
FRHC
Q4 25
$6.6M
$76.2M
Q3 25
$373.0K
$38.7M
Q2 25
$9.4M
$30.4M
Q1 25
$6.7M
$-142.7M
Q4 24
$-7.8M
$78.3M
Q3 24
$16.1M
$114.7M
Q2 24
$19.2M
$34.4M
Q1 24
$14.8M
$95.2M
Gross Margin
ASTH
ASTH
FRHC
FRHC
Q4 25
96.0%
Q3 25
97.1%
Q2 25
97.4%
Q1 25
96.6%
Q4 24
98.6%
Q3 24
99.1%
Q2 24
99.0%
Q1 24
Operating Margin
ASTH
ASTH
FRHC
FRHC
Q4 25
1.9%
14.9%
Q3 25
2.0%
11.5%
Q2 25
3.1%
7.6%
Q1 25
3.3%
-42.7%
Q4 24
0.1%
15.0%
Q3 24
5.9%
22.1%
Q2 24
6.2%
9.2%
Q1 24
7.5%
22.5%
Net Margin
ASTH
ASTH
FRHC
FRHC
Q4 25
0.7%
12.1%
Q3 25
0.0%
7.4%
Q2 25
1.4%
5.7%
Q1 25
1.1%
-39.2%
Q4 24
-1.2%
11.9%
Q3 24
3.4%
19.7%
Q2 24
3.9%
7.6%
Q1 24
3.7%
20.5%
EPS (diluted)
ASTH
ASTH
FRHC
FRHC
Q4 25
$0.12
$1.25
Q3 25
$0.01
$0.63
Q2 25
$0.19
$0.50
Q1 25
$0.14
$-2.35
Q4 24
$-0.14
$1.29
Q3 24
$0.33
$1.89
Q2 24
$0.40
$0.57
Q1 24
$0.31
$1.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
FRHC
FRHC
Cash + ST InvestmentsLiquidity on hand
$429.5M
$869.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$1.4B
Total Assets
$2.2B
$12.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
FRHC
FRHC
Q4 25
$429.5M
$869.2M
Q3 25
$463.4M
$636.0M
Q2 25
$342.1M
$567.9M
Q1 25
$260.9M
$837.3M
Q4 24
$290.8M
$577.9M
Q3 24
$350.3M
$569.2M
Q2 24
$327.7M
$718.7M
Q1 24
$337.3M
$545.1M
Stockholders' Equity
ASTH
ASTH
FRHC
FRHC
Q4 25
$779.3M
$1.4B
Q3 25
$775.5M
$1.2B
Q2 25
$765.5M
$1.2B
Q1 25
$745.4M
$1.2B
Q4 24
$712.7M
$1.3B
Q3 24
$704.6M
$1.3B
Q2 24
$678.9M
$1.1B
Q1 24
$653.5M
$1.2B
Total Assets
ASTH
ASTH
FRHC
FRHC
Q4 25
$2.2B
$12.4B
Q3 25
$2.2B
$10.3B
Q2 25
$1.4B
$9.7B
Q1 25
$1.3B
$9.9B
Q4 24
$1.4B
$9.1B
Q3 24
$1.3B
$8.8B
Q2 24
$1.3B
$8.5B
Q1 24
$1.2B
$8.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
FRHC
FRHC
Operating Cash FlowLast quarter
$-2.9M
$717.8M
Free Cash FlowOCF − Capex
$-6.0M
$651.7M
FCF MarginFCF / Revenue
-0.6%
103.7%
Capex IntensityCapex / Revenue
0.3%
10.5%
Cash ConversionOCF / Net Profit
-0.44×
9.42×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
FRHC
FRHC
Q4 25
$-2.9M
$717.8M
Q3 25
$10.0M
$535.3M
Q2 25
$90.9M
$480.8M
Q1 25
$16.6M
$1.3B
Q4 24
$-10.9M
$-72.8M
Q3 24
$34.0M
$-438.0M
Q2 24
$23.2M
$854.1M
Q1 24
$6.0M
$309.0M
Free Cash Flow
ASTH
ASTH
FRHC
FRHC
Q4 25
$-6.0M
$651.7M
Q3 25
$7.4M
$456.4M
Q2 25
$89.5M
$450.0M
Q1 25
$13.6M
Q4 24
$-13.5M
$-92.7M
Q3 24
$31.7M
$-447.5M
Q2 24
$20.4M
$829.9M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
FRHC
FRHC
Q4 25
-0.6%
103.7%
Q3 25
0.8%
86.7%
Q2 25
13.7%
84.4%
Q1 25
2.2%
Q4 24
-2.0%
-14.1%
Q3 24
6.6%
-77.0%
Q2 24
4.2%
184.1%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
FRHC
FRHC
Q4 25
0.3%
10.5%
Q3 25
0.3%
15.0%
Q2 25
0.2%
5.8%
Q1 25
0.5%
Q4 24
0.4%
3.0%
Q3 24
0.5%
1.6%
Q2 24
0.6%
5.4%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
FRHC
FRHC
Q4 25
-0.44×
9.42×
Q3 25
26.69×
13.82×
Q2 25
9.65×
15.82×
Q1 25
2.48×
Q4 24
-0.93×
Q3 24
2.11×
-3.82×
Q2 24
1.21×
24.83×
Q1 24
0.40×
3.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

FRHC
FRHC

Segment breakdown not available.

Related Comparisons